News and Trends 23 Oct 2018 Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a deal worth up to €600M. The two companies will collaborate in the development and commercialization of Enterome’s lead microbiome-targeting treatment currently in Phase I trials. Under the terms of the deal, Takeda will pay Enterome €44M upfront, and up to […] October 23, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 16 Oct 2018 Using the Skin Microbiome to Treat Acne The microbes living on our skin can play an important role in skin conditions such as acne. Philip talked to Veronika Oudova, CEO and co-founder of the Belgian company S-Biomedic, about how the company plans to fight acne with microbes, and the challenges of launching products in a field that is still unfamiliar to regulators. […] October 16, 2018 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2018 Microsoft Signs its First Microbiome Partnership Microsoft Genomics will work with Cambridge-based Eagle Genomics to scale up its artificial intelligence platform for microbiome research. In recent years, it has become evident that the microbes that inhabit our body are key to our health. The microbiome has been linked to conditions such as diabetes, cancer, Alzheimer’s, multiple sclerosis and many more. However, large-scale studies […] October 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2018 Update: Series A Boost Pushes Belgian Microbiome Spin-Off Forward Update (27/09/2018): New investment from Dutch venture capital fund Innovation Industries brings A-Mansia’s Series A round up to €18M. The company’s first human study of the effects of A. muciniphila in volunteers is currently underway at the University of Louvain. Published on 27/04/2018 A-Mansia Biotech has raised €13M in Series A financing led by Seventure Partners. The […] September 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2018 Art Made With Kombucha Explores the Science of the Microbiome Artist Alanna Lynch uses kombucha as an art medium to explore our relationship with the microbiome, which is now in the spotlight of human health. An ancient drink made of fermented tea, kombucha is now, over 2,000 years later, exploding in popularity. This week, Coca-Cola acquired an Australian kombucha company in an aim to enter […] September 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2018 Modulating the Microbiome Could Boost Vaccine Performance Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […] August 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2018 Precision Antibiotic Improves Outcome of Gut Infections in Phase II Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more effective in reducing the recurrence of the disease than the standard of care. Clostridium difficile is a bacterium that can infect the gut after a patient receives broad spectrum antibiotics. C. difficile infections typically cause diarrhoea and abdominal pain, but […] August 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 25 Jul 2018 Could These Groundbreaking Therapies Make Conventional Antibiotics a Thing of the Past? With the rise of antimicrobial resistance across the globe, and with a dire lack of new antibiotics in the pipeline, more attention is going towards developing innovative treatments and technologies that kill superbugs in completely new ways. Here, we take a closer look at some of the most promising of these technologies emerging from the […] July 25, 2018 - 5 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2018 Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical trials. The treatment uses a bacterium found in the gut to prevent and dampen inflammation. The company, based in Paris, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the […] July 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2018 Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […] June 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 21 Mar 2018 Do Phages Hold the Key to Modulating the Microbiome? The human microbiome is emerging as a target for treating a wide range of diseases, but it’s still a young field and there are lots of unknowns. Philip discussed with the CEO of BiomX whether phages may be the key to targeting specific bacterial strains in the microbiome. In the last decade, scientists have found […] March 21, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 19 Mar 2018 Could the Microbiome Treat Side Effects of Stem Cell Transplants? MaaT Pharma, based in Lyon, has received authorization to launch a Phase II trial for its therapy, which targets the gut microbiota to treat complications from stem cell transplants. MaaT Pharma will launch a Phase II trial for MaaT013, a therapy for treating acute graft-versus-host disease — a major complication of hematopoietic stem cell transplantation […] March 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email